October 1, 2017
In a first-of-its-kind study, University of California San Diego School of Medicine researchers report that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.
June 3, 2021
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
October 17, 2022
Researchers led by Nicole Steinmetz, professor of nanoengineering at the University of California San Diego, have received $4.3 million in grants from the National Institutes of Health (NIH) to advance their research using plant viruses to develop cancer immunotherapies.
September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy’s effectiveness.
August 28, 2017
…could be used to improve how well vaccines and immunotherapies work and how long they last.
July 18, 2016
…UC San Diego Health, where he underwent experimental cancer immunotherapy, which has now eradicated the tumor.
April 19, 2017
…would survive tongue cancer but after participating in an immunotherapy clinical trial at Moores Cancer Center at UC San Diego Health, he was declared cancer-free in July 2016. To give back, Rockett is now asking concert-goers to join him in supporting immunotherapy at Moores Cancer Center.
April 1, 2019
Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients.
September 20, 2018
…September 20 in Cell, may help researchers improve cancer immunotherapies and predict which patients will respond best.
March 13, 2023
UC San Diego researchers have identified a strong association between the product of a gene expressed in most cancers and elevated levels of white blood cells that produce antibodies within tumors, suggesting a new therapeutic target.
